Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 11/20 | 0.88 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.74 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15528928 | 0.94 | RXFP1 (1.00) | RXFP1 | |
| SCHEMBL15528441 | 0.94 | RXFP1 (0.79) | RXFP1KCNK3KCNK9CYP1A2CYP3A4 | |
| SCHEMBL15528979 | 0.93 | RXFP1 (0.78) | RXFP1KCNK3KCNK9CYP1A2CYP3A4 | |
| SCHEMBL15530591 | 0.89 | RXFP1 (0.72) | RXFP1KCNK3KCNK9CYP1A2CYP3A4 | |
| SCHEMBL15529016 | 0.88 | RXFP1 (1.00) | RXFP1 | |
| SCHEMBL2699662 | 0.87 | RXFP1 (0.69) | RXFP1CYP1A2CYP3A4MAPTCYP2C19 | |
| SCHEMBL15528909 | 0.87 | RXFP1 (1.00) | RXFP1 | |
| SCHEMBL28037920 | 0.87 | RXFP1 (0.69) | RXFP1CYP1A2CYP3A4MAPTCYP2C19 | |
| SCHEMBL15529040 | 0.87 | RXFP1 (0.69) | RXFP1KCNK3KCNK9CYP1A2CYP3A4 | |
| SCHEMBL15529586 | 0.87 | RXFP1 (0.90) | RXFP1KCNK3KCNK9CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | claimed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | claimed |
| US-20130109698-A1 | Small Molecule Inhibitors of Functions of the HIV-1 Matrix Protein | DREXEL UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109698-A1 | Small Molecule Inhibitors of Functions of the HIV-1 Matrix Protein | SERPINB1, TIMP3, MIF | RXFP1 3707/4885KCNK3 4665/4885KCNK9 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.